Summary

Exenatide is a synthetic version of exendin-4, a peptide originally isolated from the saliva of the Gila monster lizard. It was the first GLP-1 receptor agonist to receive regulatory approval (2005, FDA; 2007, EMA) and established the incretin mimetic class for type 2 diabetes. Exenatide improves glycaemic control by enhancing glucose-dependent insulin secretion, suppressing glucagon, and slowing gastric emptying. Both twice-daily (Byetta) and once-weekly (Bydureon) formulations have been studied extensively. This profile is for research and educational purposes only.

Mechanism

Exenatide is a potent agonist of the GLP-1 receptor, a G-protein-coupled receptor expressed on pancreatic beta cells, alpha cells, and neurons in the central nervous system and gastrointestinal tract. Its primary effects are: (1) glucose-dependent enhancement of insulin secretion from pancreatic beta cells — insulin release increases when blood glucose is elevated and diminishes as glucose normalises, reducing hypoglycaemia risk; (2) suppression of glucagon secretion from alpha cells in a glucose-dependent manner; (3) slowing of gastric emptying, which reduces postprandial glucose excursions; and (4) central appetite suppression contributing to weight loss. Unlike endogenous GLP-1, exendin-4 is resistant to DPP-4 degradation, conferring a plasma half-life of approximately 2.4 hours (Byetta) and enabling once-weekly dosing with the extended-release formulation.

Evidence base

Exenatide has one of the most extensive clinical evidence bases among peptide therapeutics, with over two decades of published research including the AMIGO phase 3 programme, the DURATION head-to-head trials, and the large-scale EXSCEL cardiovascular outcomes trial. Evidence for glycaemic efficacy is strong. Cardiovascular benefit was not definitively demonstrated (EXSCEL missed its superiority endpoint narrowly). Weight loss effects are moderate and well-characterised. Long-term safety data span more than 15 years of real-world use.

Protocols

Exenatide is a licensed prescription medicine. In clinical practice, Byetta is initiated at 5 mcg twice daily subcutaneously (within 60 minutes before morning/evening meals), titrated to 10 mcg twice daily after one month. Bydureon is administered as 2 mg once weekly subcutaneously. These protocols are described for research reference only and do not constitute dosing advice.

Exenatide is classified as a Prescription-Only Medicine (POM) in the United Kingdom. Both Byetta and Bydureon are licensed by the MHRA. Supply without prescription is unlawful. For research-purchase contexts, exenatide sold by non-pharmacy vendors as a 'research peptide' should be regarded with extreme caution, as it is a licensed medicine and counterfeit risk is high.

Vendor notes

Exenatide is a licensed POM and should only be obtained through registered pharmacies with a valid prescription. We do not list research-grade vendors for this compound due to its status as an approved medicine with well-established pharmacy supply chains. Researchers seeking exenatide for in vitro or animal studies should source from established biochemical supply companies (e.g., Sigma-Aldrich, Tocris) with appropriate COAs.

References

  1. Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27(11):2628–2635.
  2. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28(5):1083–1091.
  3. DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28(5):1092–1100.
  4. Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes. Lancet. 2008;372(9645):1240–1250.
  5. Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228–1239.